Renascience Answers Shareholder Queries on Development Milestones and Strategies

TOKYO, Jun 29 (Pulse News Wire) – Renascience Inc. Regarding the upcoming Super Human Summit, the company stated it did not participate but emphasized its commitment to advancing clinical trials for chronic myeloid leukemia (CML).

The Phase III trial results are expected to be disclosed by the end of the fiscal year, contingent upon data analysis completion in September. In response to concerns about potential setbacks in clinical trials, Renascience highlighted its diversified approach to mitigate risks through multiple development pipelines. The company also indicated ongoing discussions with several domestic and international firms for licensing and sales partnerships should the CML drug gain approval.

Additionally, Renascience confirmed its focus remains on human pharmaceuticals while exploring opportunities in veterinary medicine concurrently. Regarding delays in Eliion's hair loss Phase II trial, Renascience attributed the delay primarily to non-clinical testing and funding challenges in Eiri On Sha Gawa. The company noted that projected earnings forecasts for the current fiscal period do not factor in revenue contributions from Eliion.

Further updates on XPRIZE outcomes will be communicated once formal announcements are made.